{"totalCount":3,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06944379","orgStudyIdInfo":{"id":"ORKA-002-211"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose","officialTitle":"Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-04-15","studyFirstSubmitQcDate":"2025-04-23","studyFirstPostDateStruct":{"date":"2025-04-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-25","lastUpdatePostDateStruct":{"date":"2025-09-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.","detailedDescription":"This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) of ORKA-002 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-002 dose will be administered by a subcutaneous injection."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["ORKA-002","Phase 1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ORKA-002","type":"EXPERIMENTAL","description":"Subcutaneous (SC) injection of ORKA-002","interventionNames":["Drug: ORKA-002"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Subcutaneous (SC) injection of placebo comparator","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-002","description":"ORKA-002 is supplied as sterile solution to be administered by SC injection","armGroupLabels":["ORKA-002"]},{"type":"OTHER","name":"Placebo","description":"Placebo solution to be administered at a matching volume by SC injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Treatment-emergent Adverse Events","description":"Incidence of treatment-emergent adverse events and clinically significant changes from baseline in vital signs, electrocardiograms, and clinical laboratory parameters","timeFrame":"Day 1 through 1 year"}],"secondaryOutcomes":[{"measure":"Maximum observed serum concentration of ORKA-002","description":"Cmax of ORKA-002","timeFrame":"Day 1 through 1 year"},{"measure":"Time to Cmax (Tmax) of ORKA-002","description":"Tmax of ORKA-002","timeFrame":"Day 1 through 1 year"},{"measure":"Area under the serum concentration-time curve (AUC) of ORKA-002","description":"Area under the curve from the time of dosing to infinity (AUC0-inf)","timeFrame":"Day 1 through 1 year"},{"measure":"Terminal elimination half-life (T1/2)","description":"T1/2 of ORKA-002","timeFrame":"Day 1 through 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Healthy male or female participants\n2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2 at Screening\n3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit(s)/s defined in the protocol\n4. Using two methods of contraception (one being highly effective) from admission through the end of the study\n\nKey Exclusion Criteria:\n\n1. Any clinically significant medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.\n2. Known history of illicit drug use or drug abuse or harmful alcohol use\n3. Known history of frequent tobacco or vaping use within 2 years prior to screening\n4. Unwilling to abstain from regular, continuous alcohol use or tobacco use as per protocol\n5. History of severe allergic reactions or hypersensitivity\n6. Actively nursing, lactating, pregnant, or plans to be pregnant\n7. Use of any investigational drug therapy within 30 days prior to enrollment\n8. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kyle Breitschwerdt","affiliation":"Oruka Therapeutics, Inc.","role":"STUDY_DIRECTOR"},{"name":"Principal Investigator","affiliation":"Oruka Therapeutics Investigative Site","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","city":"Christchurch","state":"New Zealand","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07090330","orgStudyIdInfo":{"id":"ORKA-001-112"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis","acronym":"EVERLAST-A"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-21","studyFirstSubmitQcDate":"2025-07-21","studyFirstPostDateStruct":{"date":"2025-07-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-30","lastUpdatePostDateStruct":{"date":"2025-11-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.","detailedDescription":"This is a proof-of-concept study evaluating ORKA-001 in patients with moderate-to-severe psoriasis with study drug administration divided into an Induction period followed by a Maintenance period. Following completion of the Maintenance period at Week 52, participants will have the option to enter into the open-label extension (OLE) study."},"conditionsModule":{"conditions":["Plaque Psoriasis"],"keywords":["Phase 2","ORKA-001","Plaque psoriasis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":80,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"(Induction Period) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Induction regimen.","interventionNames":["Drug: ORKA-001 Induction Dose"]},{"label":"(Induction Period) Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive Placebo per protocol Induction regimen.","interventionNames":["Other: Placebo"]},{"label":"(Maintenance Period - Arm 1) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Drug: ORKA-001 Maintenance Dose"]},{"label":"(Maintenance Period - Arm 2) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Drug: ORKA-001 Maintenance Dose"]},{"label":"(Maintenance Period - Arm 3) Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-001 Induction Dose","description":"ORKA-001 Induction Dose, administered by subcutaneous (SC) injection","armGroupLabels":["(Induction Period) ORKA-001"]},{"type":"OTHER","name":"Placebo","description":"Placebo administered by subcutaneous (SC) injection","armGroupLabels":["(Induction Period) Placebo","(Maintenance Period - Arm 3) Placebo"]},{"type":"DRUG","name":"ORKA-001 Maintenance Dose","description":"ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection","armGroupLabels":["(Maintenance Period - Arm 1) ORKA-001","(Maintenance Period - Arm 2) ORKA-001"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 16"}],"secondaryOutcomes":[{"measure":"Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16","description":"Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 52","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 52","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 52","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 52","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 52"},{"measure":"Incidence of Treatment-emergent Adverse Events","description":"Incidence of treatment adverse events and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms","timeFrame":"Day 1 through 52 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants ≥ 18 years of age\n2. Have a diagnosis of plaque psoriasis for \\> 6 months\n3. Have moderate-to-severe chronic plaque psoriasis defined as:\n\n   1. BSA ≥ 10%, and\n   2. PASI ≥ 12, and\n   3. IGA score of ≥ 3 on a 5-point scale\n4. Candidate for systemic therapy or phototherapy\n5. Women of childbearing potential must have a negative pregnancy test\n\nExclusion Criteria:\n\n1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis\n2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease\n3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence\n4. A known hypersensitivity to any components of the ORKA-001 drug product\n5. Women who are breastfeeding or plan to breastfeed during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Oruka Clinical Trials Information","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90045","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"San Diego","state":"California","zip":"92123","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Santa Ana","state":"California","zip":"92701","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Santa Monica","state":"California","zip":"90404","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Cromwell","state":"Connecticut","zip":"06416","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":41.5951,"lon":-72.64537}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Rolling Meadows","state":"Illinois","zip":"60008","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.08419,"lon":-88.01313}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Bowling Green","state":"Kentucky","zip":"42104","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":36.99032,"lon":-86.4436}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02111","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"New York","state":"New York","zip":"10023","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Portland","state":"Oregon","zip":"97201","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T5J 3S9","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T6G 1C3","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Surrey","state":"British Columbia","zip":"V3R 6A7","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":49.10635,"lon":-122.82509}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Hamilton","state":"Ontario","zip":"L8N 1Y2","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"London","state":"Ontario","zip":"N6H 5LS","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Markham","state":"Ontario","zip":"L3P 1X3","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.86682,"lon":-79.2663}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Peterborough","state":"Ontario","zip":"K9J 5K2","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":44.30012,"lon":-78.31623}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M4W 2N4","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Waterloo","state":"Ontario","zip":"N2J 1C4","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.4668,"lon":-80.51639}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06698939","orgStudyIdInfo":{"id":"ORKA-001-111"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-001 in Healthy Volunteers","officialTitle":"Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of ORKA-001 in Healthy Participants","acronym":"ORKA-001-111"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-12-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-11-13","studyFirstSubmitQcDate":"2024-11-18","studyFirstPostDateStruct":{"date":"2024-11-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-15","lastUpdatePostDateStruct":{"date":"2025-05-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.","detailedDescription":"This is a single center, phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-001 dose will be administered by a subcutaneous injection."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["ORKA-001","Phase 1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive subcutaneous injection of ORKA-001 at either 300 mg, 600 mg or 1200 mg.","interventionNames":["Drug: ORKA-001"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive a subcutaneous injection of placebo comparator.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-001","description":"ORKA-001 is supplied as sterile solution to be administered by SC injection","armGroupLabels":["ORKA-001"]},{"type":"OTHER","name":"Placebo","description":"Placebo solution to be administered at a matching volume by SC injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and frequency of Treatment-Emergent Adverse Events [Safety and Tolerability]","description":"Incidence of treatment-emergent adverse events (TEAEs) and clinically significant changes from baseline in vital signs, electrocardiograms (ECGs), clinical laboratory parameters, and physical examinations.","timeFrame":"Day 1 through one year"}],"secondaryOutcomes":[{"measure":"Maximum observed serum concentration of ORKA-001","description":"CMax of ORKA-001","timeFrame":"Day 1 through one year"},{"measure":"Time to CMax (TMax) of ORKA-001","description":"TMax of ORKA-001","timeFrame":"Day 1 through one year"},{"measure":"Area Under the Serum Concentration-Time Curve (AUC) of ORKA-001","description":"Area under the curve from the time of dosing to infinity (AUC0-inf)","timeFrame":"Day 1 through one year"},{"measure":"Terminal elimination half-life (T1/2)","description":"T1/2 of ORKA-001","timeFrame":"Day 1 through one year"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Healthy male or female participants\n2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2\n3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit/s defined in the protocol\n4. Using a highly effective method of contraception from admission through the end of the study.\n5. Willing to abstain from regular, continuous alcohol use or tobacco use as per protocol\n\nKey Exclusion Criteria:\n\n1. Any clinically significant medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.\n2. Known history of illicit drug use or drug abuse or harmful alcohol use\n3. Known history of frequent tobacco or vaping use within 2 years prior to Screening\n4. History of severe allergic reactions or hypersensitivity\n5. Actively nursing or lactating\n6. Use of investigational drug therapy within 30 days prior to enrollment\n7. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kyle Breitschwerdt","affiliation":"Oruka Therapeutics, Inc.","role":"STUDY_DIRECTOR"},{"name":"Principal Investigator","affiliation":"Oruka Therapeutics Investigative Site","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}
]}